Clinical Effects of Torasemide Prolonged Release in Mild‐to‐Moderate Hypertension: A Randomized Noninferiority Trial Versus Torasemide Immediate Release
The efficacy of a new torasemide prolonged release (PR) formulation to torasemide immediate release (IR) was compared in a randomized noninferiority double‐blind trial. Patients with newly diagnosed mild‐to‐moderate hypertension or unresponsive or poor tolerability to previous antihypertensive monot...
Saved in:
Published in | Cardiovascular therapeutics Vol. 26; no. 2; pp. 91 - 100 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Malden, USA
Blackwell Publishing Inc
2008
Wiley Blackwell |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The efficacy of a new torasemide prolonged release (PR) formulation to torasemide immediate release (IR) was compared in a randomized noninferiority double‐blind trial. Patients with newly diagnosed mild‐to‐moderate hypertension or unresponsive or poor tolerability to previous antihypertensive monotherapy received 5 mg/day of torasemide‐PR (n = 219) or torasemide‐IR (n = 223) for 12 weeks (uptitration to 10 mg/day if no response at 4 or 8 weeks). Mean diastolic blood pressure (DBP) reduction in the torasemide‐PR group (11.6 ± 7.1 mmHg, 95% confidence interval [CI] 10.6–12.5) versus torasemide‐IR (11.3 ± 7.5 mmHg, 95% CI 10.2–12.3) met the noninferiority criterion of a nonsided 97.5% CI lower than the preestablished margin of 2 mmHg. A significantly higher percentage of patients in the torasemide‐PR group achieved adequate BP control after 8 and 12 weeks. Ambulatory 24‐h BP monitoring (ABPM) measurements in a subset of 100 patients showed greater daytime SBP reductions in the torasemide‐PR group (128.4 ± 9.9 mmHg vs. 133.5 ± 10.4 mmHg, P < 0.05). Safety and tolerability of both formulations were similar. |
---|---|
Bibliography: | For details of the Torasemide‐PR in Hypertension Clinical Trial Investigators Group, please see the At the time of submission of the article, torasemide‐PR has been approved by the Spanish Health authorities. appendix Trial registration: EudraCT 2004‐000876‐14. . |
ISSN: | 1755-5914 1755-5922 |
DOI: | 10.1111/j.1527-3466.2008.00046.x |